Wells Fargo Maintains Equal-Weight on DICE Therapeutics, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila maintains an Equal-Weight rating on DICE Therapeutics (NASDAQ:DICE) and raises the price target from $38 to $48.
June 20, 2023 | 4:55 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wells Fargo maintains an Equal-Weight rating on DICE Therapeutics and raises the price target from $38 to $48.
The news directly mentions DICE Therapeutics and the price target increase by Wells Fargo analyst Derek Archila. This indicates that the analyst sees potential in the stock, but the Equal-Weight rating suggests that the stock is fairly valued at the moment. The short-term impact on the stock price is likely to be neutral as the rating remains unchanged.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100